Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
UK law firm Potter Clarkson has elected Michael Pears as partner in the firm’s biotechnology and pharmaceuticals department.   5 January 2016
Asia
Roche has settled its patent litigation dispute with India-based Glenmark Pharmaceuticals centring on cancer drug Tarceva.   4 January 2016
Big Pharma
Germany-based healthcare company Bayer HealthCare has sued Mylan Pharmaceuticals over the alleged infringement of five of its patents.   22 December 2015
Americas
The smartphone wars may have slowed down but many smaller high-tech companies continue to assert their IP rights against competitors, as the fitness tracker battle shows. Fabio Marino and Luc Dahlin of McDermott Will & Emery report.   22 December 2015
Big Pharma
India-based life sciences company Glenmark Pharmaceuticals has confirmed that it has ended its patent dispute with Forest Laboratories.   21 December 2015
Big Pharma
The US Court of Appeals for the Federal Circuit’s affirmation of the Patent Trial and Appeal Board’s decision to invalidate a Merck patent used to reduce homocysteine in the human body faced criticism from a dissenting judge, who claimed the court showed too much deference to the body’s decision.   18 December 2015
Generics
Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.   17 December 2015
Big Pharma
The complex rules around the filing of divisional applications relating to priority of patent claims are designed to maintain the integrity of the first-to-file system, as Ashley Roughton of Nabarro explains.   17 December 2015
Americas
Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.   16 December 2015
Americas
Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.   15 December 2015